Luteal phase defects following agonist-triggered ovulation: a patient-dependent response

Area of Science:

• Reproductive Endocrinology
• Pharmacology

Background:

• The luteal phase (LP) is critical for successful implantation and pregnancy.
• Ovulation induction using GnRH agonists like triptorelin can sometimes lead to inadequate luteal phases.
• Understanding factors influencing LP post-triptorelin is crucial for optimizing fertility treatments.

Purpose of the Study:

• To investigate the luteal phase characteristics in patients undergoing ovulation induction with triptorelin.
• To evaluate the efficacy of different triptorelin dosages and luteal support strategies in cases of inadequate luteal phase.
• To identify potential patient-specific factors contributing to defective luteal phases after triptorelin administration.

Main Methods:

• Patients received triptorelin 0.1 mg for ovulation induction.
• Non-pregnant patients in the first cycle were randomized for a second cycle with varying triptorelin doses or luteal support (progesterone or HCG).
• Luteal phase length and pregnancy rates were assessed.

Main Results:

• An inadequate luteal phase was observed in 34.4% of non-conceptional cycles.
• Repeating or increasing triptorelin dosage did not improve defective luteal phases or pregnancy rates.
• Luteal support with oral micronized progesterone or HCG significantly improved luteal phase and pregnancy rates.
• Luteal phase patterns were consistent within individual patients across cycles.

Conclusions:

• Defective luteal phases after triptorelin-triggered ovulation are patient-dependent, likely related to individual pre-ovulatory surge profiles.
• Luteal support is more effective than dose escalation of triptorelin in managing defective luteal phases.
• Personalized management strategies are needed for patients experiencing luteal phase dysfunction post-ovulation induction.